prnewswire.com · 3 jul

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

businesswire.com · 23 jun

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026.

marketbeat.com · 10 jun

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape

Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.

seekingalpha.com · 10 jun

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

gurufocus.com · 8 jun

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

[url="]Amylyx Pharmaceuticals, Inc.[/url] (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine

businesswire.com · 8 jun

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026.

globenewswire.com · 8 jun

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Amylyx Pharmaceuticals, Inc. – AMLX

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of publicly traded securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX): SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION To: All those who purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx”) securities between November 11, 2022, and November 8, 2023, inclusive (the “Class Period”), and who were allegedly damaged thereby (the “Settlement Class”). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts, that Plaintiff Oliver Shih, on behalf of himself and all members of the proposed Settlement Class, and Amylyx, Joshua B.

businesswire.com · 15 may

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal. The publication reports Week 24 and Week 48 results from the Phase 2 ope.